FRES SE&CNPV logo

FRES SE&CNPV

Stock
Stock
ISIN: DE000FRE5EN2
Ticker: FRE
DE000FRE5EN2
FRE

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

FRES SE&CNPV has so far distributed $1.221 in 2026. The next dividend will be paid on 27.05.2027


$0.458

CHART BY

Frequently asked questions

The market capitalization of FRES SE&CNPV is $29.25B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for FRES SE&CNPV is 16.86. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
FRES SE&CNPV's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $3.079. EPS indicates the company's profitability on a per-share basis.
Currently, 17 analysts cover FRES SE&CNPV's stock, with a consensus target price of $63.14. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, FRES SE&CNPV reported a revenue of $26.67B.
FRES SE&CNPV's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $3.84B. EBITDA measures the company's overall financial performance.
FRES SE&CNPV has a free cash flow of $1.65B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
FRES SE&CNPV employs approximately 178,394 people. It operates in the Health Care sector, specifically within the Hospital/ Nursing Management industry.
The free float of FRES SE&CNPV is 410.55M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$29.25B
EPS (TTM) 
$3.079
Free Float 
410.55M
P/E ratio (TTM) 
16.86
Revenue (TTM) 
$26.67B
EBITDA (TTM) 
$3.84B
Free Cashflow (TTM) 
$1.65B

Pricing

1D span
$51.52$52.72
52W span
$40.81$62.35

Analyst Ratings

The price target is $63.14 and the stock is covered by 17 analysts.

Buy

16

Hold

1

Sell

0

Information

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.

Employees
178,394
Industries
Hospital/ Nursing Management
Sector
Health Care

Identifier

ISIN
DE000FRE5EN2
Primary Ticker
FRE

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation